China International Capital Corp

US-listed hybrid electric vehicle maker Li Auto has hit the road for its Hong Kong secondary listing. The deal could raise around HK$13.1bn ($1.68bn) based on the last close of its US stock.

Online music platform Cloud Village is drumming up demand for its Hong Kong listing, according to a source familiar with the matter.

Chinese biopharmaceutical company I-Mab is moving ahead with plans for a dual listing in Shanghai, as it looks to broaden its investor base.

Hybrid electric vehicle maker Li Auto received the go ahead from Hong Kong’s stock exchange for a secondary listing.

Hong Kong’s stock exchange has rejected an IPO application from Aim Vaccine, a leading Chinese vaccine maker. The deal is being sponsored by China Securities, CICC, Goldman Sachs and Macquarie.

LinkDoc Technology, a cancer-focused medical data company, has shelved its US IPO just hours before pricing, as Chinese technology stocks recoil from Beijing’s clampdown on overseas listings.

Chinese biotechnology company Brii Biosciences has raised HK$2.48bn ($319.7m) from its Hong Kong IPO, after pricing the deal at the top of the marketed range.

Medlive Technology and Brii Biosciences are tapping investors for a combined HK$6.7bn ($863m).

Chinese ride-hailing giant Didi has raised $4.4bn from its New York Stock Exchange IPO, increasing the size of the float after investors pumped more than $40bn of orders into the book.

Kindstar Globalgene Technology and Dexin Services Group both rolled out their Hong Kong IPOs on Tuesday.

Chinese biotechnology company Keymed Biosciences has hit the market with an up to HK$3.1bn ($400.1m) IPO.

Chinese online grocer Missfresh saw its share price sink on its trading debut, after it priced its Nasdaq IPO at the bottom of the marketed range.